A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
← catalyst calendarSponsored by H. Lundbeck A/S (industry) · HLUN-B.CO — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
874actual
Sites
120
Countries
Bulgaria, Czechia, Denmark +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-01 | actual | When the study began enrolling |
| Primary completion | 2026-01-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-16 | actual | The whole study's end, after follow-up |
| First posted | 2024-03-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Drug: Lu AG09222
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in the Number of Monthly Migraine Days (MMDs)
measured Baseline up to Week 12 (Weeks 1-12)
Permalink · HLUN-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed